三元生物(301206) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥150,204,941.37, a decrease of 21.73% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥24,913,986.70, representing a year-on-year increase of 2.75%[4]. - Total operating revenue for the current period is ¥150,204,941.37, a decrease of 21.8% from ¥191,894,599.16 in the previous period[30]. - Net profit for the current period is ¥24,891,688.68, slightly up from ¥24,247,672.28, indicating a growth of 2.7%[31]. - The total comprehensive income for the current period is ¥24,891,688.68, compared to ¥24,247,672.28 in the previous period, reflecting a growth of 2.7%[32]. Cash Flow - Cash flow from operating activities increased by 83.98% to ¥40,768,366.48, primarily due to a reduction in payments for purchased goods[4][14]. - Operating cash flow net amount increased significantly to ¥40,768,366.48 from ¥22,158,704.92, a growth of 83.9%[34]. - The company reported a significant increase of 4,774.62% in cash flow from investing activities, mainly due to the maturity of large certificates of deposit[14]. - The company experienced a significant increase in cash and cash equivalents, ending the period with ¥1,634,381,193.93, up from ¥95,348,055.91[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,751,521,629.28, a decrease of 1.12% from the end of the previous year[5]. - As of March 31, 2025, the company's total current assets amounted to RMB 2,933,444,421.90, a decrease from RMB 3,387,997,986.58 at the beginning of the period[27]. - The company's total non-current assets increased to RMB 1,818,077,207.38 from RMB 1,417,253,752.54[28]. - The total assets of the company as of March 31, 2025, were RMB 4,751,521,629.28, down from RMB 4,805,251,739.12[28]. - The company's total liabilities decreased to RMB 258,898,969.94 from RMB 314,043,539.30[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,930[16]. - The largest shareholder, Nie Zaijian, holds 46.31% of the shares, totaling 93,698,770 shares[16]. - The second-largest shareholder, Shandong Luxin Qisheng Investment Management Co., holds 6.62% with 13,400,750 shares[16]. - The total number of restricted shares at the beginning of the period was 99,686,475, with 4,971,975 shares released during the period[19]. - The total number of restricted shares at the end of the period is 94,714,500[20]. - Nie Zaijian's restricted shares will be released on August 10, 2025, totaling 92,946,000 shares[19]. - The company has a total of 1,365,000 restricted shares held by shareholder Nie Yuyue, which will be released on February 10, 2025[20]. - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing[17]. - The top 10 shareholders include a mix of individual and institutional investors, with significant holdings by private equity funds[16]. - The company has not disclosed any other relationships or agreements among the top shareholders[17]. Research and Development - Research and development expenses decreased by 38.46% compared to the same period last year, as existing projects reached completion and new projects are still under evaluation[13]. - Research and development expenses decreased to ¥9,744,135.17 from ¥15,833,077.03, a reduction of 38.5%[30]. Other Financial Activities - The company is undergoing a correction of prior accounting errors as mandated by the regulatory authority, which will not affect the overall financial position[6]. - The company approved the use of surplus funds amounting to RMB 79,399.00 million for permanent working capital, representing 29.99987% of the total surplus funds[22]. - The company plans to use up to RMB 190,000 million of temporarily idle surplus funds for cash management within 12 months[23]. - The company will continue to use up to RMB 200,000 million of temporarily idle self-owned funds for cash management, also within 12 months[24]. - The company has completed the investment project for an annual production of 50,000 tons of erythritol and will use the surplus funds of RMB 352.2712 million for daily operations[21]. - The company has authorized management to make investment decisions within the approved limits for cash management activities[23]. Earnings Per Share - The company's basic and diluted earnings per share remained unchanged at ¥0.12[4]. - The company reported a basic and diluted earnings per share of ¥0.12, unchanged from the previous period[32]. Audit Status - The company has not undergone an audit for the first quarter report[36].